Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 495,925 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 495,925 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29 | Direct | 46,600 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2026 Filed Jun 2, 2026 21:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 46,600 | $0.00 Strike: $7.01 | $0.00 |
DisclosureSEC source: 0001652824-26-000003 · primarydocument.xml · derivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,600 Underlying: Common Stock · 46,600 shares Expires 2036-05-29 F2 · derivative.exercise_date: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 21:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 9,807 | $0.00 | $0.00 |
DisclosureSEC source: 0001652824-26-000003 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,925 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:58 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $13.09 | $0.00 |
DisclosureSEC source: 0001652824-26-000002 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 225,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:58 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 221,753 | $13.41 | $2,973,707.73 |
DisclosureSEC source: 0001652824-26-000002 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 486,118 F2 · kind: Represents shares of common stock withheld to satisfy the exercise price and pay taxes upon the exercise of options originally granted to the reporting person on January 28, 2016, which were set to expire on January 28, 2026. The number of shares withheld was determined based on the closing price of the issuer's common stock on January 27, 2026. The transaction did not involve any open-market sale of securities. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:58 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 225,000 | $13.09 | $2,945,250.00 |
DisclosureSEC source: 0001652824-26-000002 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 707,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The previously granted option, representing a right to purchase a total of 225,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 28, 2017, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to Buy) · Derivative | 39,815 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0001562180-25-004351 · primarydocument.xml · derivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,815 Underlying: Common Stock · 39,815 shares Expires 2035-05-30 F2 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 30, 2025 subject to the continuous service of the optionee to the Issuer. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:32 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 7,768 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004351 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 482,871 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 1, 2026 subject to the continuous service of the recipient to the Issuer. Read SEC document |
| May 12, 2025 Filed May 14, 2025 20:49 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 20,602 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-25-003822 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,602 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| May 12, 2025 Filed May 14, 2025 20:49 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 20,602 | $7.91 | $163,046.29 |
DisclosureSEC source: 0001562180-25-003822 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 475,103 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $7.66 to $8.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2025 Filed May 14, 2025 20:49 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 20,602 | $3.76 | $77,463.52 |
DisclosureSEC source: 0001562180-25-003822 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 495,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 30,752 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-25-002804 · primarydocument.xml · derivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,602 Underlying: Common Stock · 30,752 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 30,752 | $3.76 | $115,627.52 |
DisclosureSEC source: 0001562180-25-002804 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:58 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 36,316 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-24-006146 · primarydocument.xml · derivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,316 shares Expires 2024-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:58 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 36,316 | $0.85 | $30,868.60 |
DisclosureSEC source: 0001562180-24-006146 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 444,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 15,369 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-005855 · primarydocument.xml · derivative · entry 6 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,354 Underlying: Common Stock · 15,369 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 15,369 | $13.96 | $214,500.52 |
DisclosureSEC source: 0001562180-24-005855 · primarydocument.xml · nonDerivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,035 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.76 to $14.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 21:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,369 | $3.76 | $57,787.44 |
DisclosureSEC source: 0001562180-24-005855 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 423,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 21:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 12,221 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-005855 · primarydocument.xml · derivative · entry 5 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,723 Underlying: Common Stock · 12,221 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 21:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 12,221 | $13.78 | $168,433.49 |
DisclosureSEC source: 0001562180-24-005855 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,035 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.76 to $13.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 21:00 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 12,221 | $3.76 | $45,950.96 |
DisclosureSEC source: 0001562180-24-005855 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 420,256 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 17, 2024 Filed Jul 18, 2024 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 2,210 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-005798 · primarydocument.xml · derivative · entry 6 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,944 Underlying: Common Stock · 2,210 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| July 17, 2024 Filed Jul 18, 2024 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,210 | $13.77 | $30,439.88 |
DisclosureSEC source: 0001562180-24-005798 · primarydocument.xml · nonDerivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,035 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.76 to $13.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 17, 2024 Filed Jul 18, 2024 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 2,210 | $3.76 | $8,309.60 |
DisclosureSEC source: 0001562180-24-005798 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 410,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 200 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-005798 · primarydocument.xml · derivative · entry 5 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,154 Underlying: Common Stock · 200 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 200 | $13.76 | $2,752.00 |
DisclosureSEC source: 0001562180-24-005798 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,035 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 16, 2024 Filed Jul 18, 2024 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 200 | $3.76 | $752.00 |
DisclosureSEC source: 0001562180-24-005798 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-004104 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,354 Underlying: Common Stock · 15,000 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, which expires on May 19, 2025, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 15,000 | $15.81 | $237,222.00 |
DisclosureSEC source: 0001562180-24-004104 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,035 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.59 to $16.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 14, 2024 Filed May 16, 2024 21:06 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $3.76 | $56,400.00 |
DisclosureSEC source: 0001562180-24-004104 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 423,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-003452 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,354 Underlying: Common Stock · 15,000 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, which expires on May 19, 2025, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 15,000 | $18.19 | $272,871.00 |
DisclosureSEC source: 0001562180-24-003452 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,035 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.82 to $18.61. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 21:05 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $3.76 | $56,400.00 |
DisclosureSEC source: 0001562180-24-003452 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 423,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 21:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-002771 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,354 Underlying: Common Stock · 15,000 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, which expires on May 19, 2025, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 21:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 15,000 | $21.86 | $327,942.00 |
DisclosureSEC source: 0001562180-24-002771 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,035 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $21.60 to $22.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 21:03 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $3.76 | $56,400.00 |
DisclosureSEC source: 0001562180-24-002771 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 423,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 23:28 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-001395 · primarydocument.xml · derivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,354 Underlying: Common Stock · 15,000 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 23:28 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,348 | $16.88 | $174,722.88 |
DisclosureSEC source: 0001562180-24-001395 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,035 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $16.78 to $17.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 23:28 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,652 | $16.47 | $76,625.88 |
DisclosureSEC source: 0001562180-24-001395 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 418,383 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.78 to $16.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 23:28 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $3.76 | $56,400.00 |
DisclosureSEC source: 0001562180-24-001395 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 423,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-24-000544 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,354 Underlying: Common Stock · 45,000 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 45,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2015, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 45,000 | $15.18 | $682,992.00 |
DisclosureSEC source: 0001562180-24-000544 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,035 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $14.52 to $15.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 23:39 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 45,000 | $3.76 | $169,200.00 |
DisclosureSEC source: 0001562180-24-000544 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Options (Right to buy) · Derivative | 305,250 | $0.00 Strike: $18.34 | $0.00 |
DisclosureSEC source: 0001562180-24-000223 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,250 Underlying: Common Stock · 305,250 shares Expires 2034-01-02 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2025 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantCommon Stock | 64,103 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-000223 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408,035 F2 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2025, January 1, 2026, January 1, 2027 and January 1, 2028 while the recipient provides continuous service to the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:07 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Tax withholdingCommon Stock | 11,357 | $17.95 | $203,858.15 |
DisclosureSEC source: 0001562180-24-000223 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343,932 F1 · shares: Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022 and January 3, 2023. The number of shares withheld was determined on January 2, 2024 based on the closing price of the issuer's common stock on December 29, 2023. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 18:38 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-23-008519 · primarydocument.xml · derivative · entry 5 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,316 Underlying: Common Stock · 1,500 shares Expires 2024-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 1,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on September 24, 2015, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 18:38 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionStock Options (Right to Buy) · Derivative | 43,500 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-23-008519 · primarydocument.xml · derivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,354 Underlying: Common Stock · 43,500 shares Expires 2025-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 43,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 9, 2016, and the balance vested in equal monthly installments over the 36 months thereafter. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 18:38 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 45,000 | $19.69 | $885,825.00 |
DisclosureSEC source: 0001562180-23-008519 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 355,289 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.48 to $20.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 18:38 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 1,500 | $0.85 | $1,275.00 |
DisclosureSEC source: 0001562180-23-008519 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 18:38 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 43,500 | $3.76 | $163,560.00 |
DisclosureSEC source: 0001562180-23-008519 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.